Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. - Wikidata - awgldk - TriplyDB

Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.

Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.

http://www.wikidata.org/entity/Q37316228

about

Management before hepatectomy for hepatocellular carcinoma with cirrhosis ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis.Multiparametric MR Imaging in Abdominal Malignancies.Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer Applications of molecular imaging.Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response HCC and angiogenesis: possible targets and future directions Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Intrahepatic cholangiocarcinoma: expert consensus statement.Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma.Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer.Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Retrospective Cohort Study.Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma.DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker.Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches.Opportunities and pitfalls of cancer imaging in clinical trials.Surgical management of proximal bile duct cancers.Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.Functional MRI and CT biomarkers in oncology.Robotic liver resection for malignancy: Current status, oncologic outcomes, comparison to laparoscopy, and future applications.Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.Multimodality treatment of intrahepatic cholangiocarcinoma: A review.The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma.Locoregional Therapies of Cholangiocarcinoma.Tamoxifen reverses the multi-drug-resistance of an established human cholangiocarcinoma cell line in combined chemotherapeutics.

P2860

Q26783874-70DDE211-5CBB-449B-9C7D-3026D2CC9A61 Q28687190-296096E1-CA1E-4D4E-AFB7-998FD37C4B23 Q30274956-BE36EE81-AE1C-4AA4-AF75-4B2151B6ABCC Q30364605-70A17B36-24F4-4F65-8E10-14A68CA2B9EA Q30448049-49480E29-BF55-4954-A588-C51466A7B7A2 Q31030824-2F134166-C1C6-4724-9A4B-D363A403C44D Q31119452-D2919E58-01EA-4BC8-AA3A-A2AB06C86A2B Q33621522-C2A28A71-4B4A-4D26-9DFB-29FC437F696A Q34089545-36B7B397-137E-4E46-B972-465BD2E06D34 Q34367593-44FDAF5D-5670-42F9-A859-80FA13223157 Q34630274-49BE3B12-399D-44CF-88E0-17A19EDB2634 Q34776912-229709B1-8DCD-4DBE-A8EF-AEC71958AB25 Q35082412-E0B3FAF2-3405-41FF-B6DB-35CF9118D2FD Q35109141-7AA86F00-51BE-4976-996D-39BD5A78F039 Q35698574-DBD2DCE1-986C-43C9-AEF6-BEF273F13797 Q35710375-536D0E7D-D777-4D29-9D77-E0F0D9A30005 Q35892542-1E114A95-2CDE-4630-8C33-5F40A4470FF8 Q35924971-BAB372D2-AA27-4FD9-8F4A-8356617B44CC Q36072776-80D1E044-2844-40C2-AB3A-D8F9DBDCC32C Q36093366-E4293B54-F607-4982-BD55-D4DFE98AF774 Q36310736-FF408D18-558F-4FFF-8AFD-104AA29A443C Q36419100-B0FDB81D-CFD5-4439-80E4-E82E3E0FB72D Q36580868-DBE6C4D2-5B35-4D15-A283-2DC39D7F266B Q36609503-CE668944-0F30-4E30-989A-2A49F0760593 Q36747536-8EDCE0D8-7775-4E5A-90BB-C362AA4BD084 Q37042355-D17CC0CF-F0C5-4485-8CAF-93D312104552 Q37296946-9E172209-6909-4043-8CF6-F57EAA5BBEBB Q37426851-89F6193C-FF8C-46D4-831E-4CFA7BCD678F Q37660658-8C46B5A0-B892-4038-B3F6-DDC7AB17965B Q37868455-FD4C62C3-95A3-4082-AD22-6CE0515440A9 Q37869334-04538D33-7E92-4BA1-818C-0104CEDA9AAA Q37990746-A92667E4-1658-4A80-91F2-65FFBEF7254D Q38155097-1EC67C56-EE33-467E-9602-3A1EAC097931 Q38314429-00C89C8B-E05B-4F3E-87FE-3A603CAE96C6 Q38539586-CDB37A00-AA52-4327-8875-4CD45A9A961D Q38607490-8F92D08D-5550-4DF1-92CC-3EBC61802B50 Q38707365-96730777-B2BA-4DCF-B821-10C60C0D3D7E Q38778958-88691366-44DC-4278-B464-7BA078D07DC5 Q38947234-93EF20EE-8F9B-4B38-BFE4-EEA4BD41EB5D Q39656626-131FE312-157F-465F-947F-5449711830C4

P2860

Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.

http://www.wikidata.org/entity/Q37316228

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@en

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@nl

type

label

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@en

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@nl

prefLabel

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@en

Regional chemotherapy for unre ...... RI as a biomarker of survival.

@nl

P1433

Q37316228-3C658D20-9E2B-4849-98F4-1DAB593FE7EE

P1476

Q37316228-397779C6-BC91-4B9F-A1DE-876D4DB2C214

P2093

Q37316228-01550388-A4F2-46A6-949B-D817870D5079

Q37316228-0DD5FE62-E7F4-42CA-B47A-DD811667384B

Q37316228-12EB7150-9CD7-4327-85C8-10F0DC7CED5C

Q37316228-1D513E90-2D26-4DB3-8D12-2DA0D36962A9

Q37316228-1DAF38F1-C08E-46F5-B302-9DD73B49780D

Q37316228-8A4B5619-56A0-4946-898A-071CD8E75538

Q37316228-9DC0E8E7-1E10-4D9E-9B72-2A5EE487A23D

Q37316228-A86F08CC-3645-4E55-968C-79809ED331DF

Q37316228-AAC3D917-9DBF-43DC-A94F-04DD378B967A

Q37316228-B3888710-0EF6-4C6D-961A-F6E073FEDE77

P2860

Q37316228-036C7C4A-4047-4F1A-88AB-B70CB9A0165C

Q37316228-11C902BD-1852-483C-A244-A6F39463E85D

Q37316228-1452AD47-DFE6-42E6-A106-5ABB299E17D8

Q37316228-21F6F0EF-6097-405D-B54B-D62ADB428CC5

Q37316228-30C6DEE6-BC1D-431A-A003-B45F348AE2AE

Q37316228-4EEF5A61-8425-48DC-B5C2-49EC51698B48

Q37316228-55D54074-ED03-4049-81AE-CF354AB167C4

Q37316228-5FB05241-723B-4E59-94C3-F7D521F1D1E8

Q37316228-6CFD3EAD-A485-4369-903C-B2BCCFD36B2F

Q37316228-73E51E99-4026-4CAF-922E-1C16DB3EC1C9

P304

Q37316228-5D19C68D-2C9A-444E-8996-C48AB7A33F12

P31

Q37316228-E33143B2-91CA-4EEF-998B-5FE5E7B2AA62

P356

Q37316228-33A8EE08-6850-49BC-ADB0-1A97EA275A0B

P433

Q37316228-BC39E498-DFC6-4FD8-BBD8-03954772CB5F

P478

Q37316228-CE1DE623-483D-4DC0-88DA-ECD8F8D6DCB2

P50

Q37316228-0331130E-DF72-497F-9485-F8111BCB7A49

Q37316228-93D2F9FB-BA19-4B5D-8E3F-4F99F37F3253

P577

Q37316228-25527E8E-262D-4F9E-A2AA-88D0E3356979

P5875

Q37316228-EF4136C4-B183-4C8E-AC12-E531E72B91C6

P698

Q37316228-177E2E22-934A-4E0B-88C5-117A69F76DD4

P921

Q37316228-3E442670-73D7-4269-80A8-C0D632F622FD

Q37316228-6C421C34-65E8-4A40-A316-AB762B9011B8

Q37316228-84012985-A4B3-4847-B354-2018E4BA3C69

P932

Q37316228-49B130A8-8BA9-4675-AA14-DCE4E68189CC

P356

P1433

Annals of Oncology

P1476

Regional chemotherapy for unre ...... MRI as a biomarker of survival

@en

P2093

A Tse

http://www.w3.org/2001/XMLSchema#string

D Haviland

http://www.w3.org/2001/XMLSchema#string

L H Blumgart

http://www.w3.org/2001/XMLSchema#string

L H Schwartz

http://www.w3.org/2001/XMLSchema#string

M D'Angelica

http://www.w3.org/2001/XMLSchema#string

M Gönen

http://www.w3.org/2001/XMLSchema#string

N Kemeny

http://www.w3.org/2001/XMLSchema#string

R Dematteo

http://www.w3.org/2001/XMLSchema#string

W R Jarnagin

http://www.w3.org/2001/XMLSchema#string

Y Fong

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Phase II study of erlotinib in patients with advanced biliary cancer.

An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

P304

1589-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP029

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

David H. Gultekin

P577

2009-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26261855

http://www.w3.org/2001/XMLSchema#string

P698

19491285

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2731015

http://www.w3.org/2001/XMLSchema#string